Get the Stockscreener App
0.6706
2.19%
-0.015
Adicet Bio Inc stock is traded at $0.6706, with a volume of 270.86K.
It is down -2.19% in the last 24 hours and up +9.74% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.6856
Open:
$0.69
24h Volume:
270.86K
Relative Volume:
0.56
Market Cap:
$55.47M
Revenue:
$38.70M
Net Income/Loss:
$-117.88M
P/E Ratio:
-0.3945
EPS:
-1.7
Net Cash Flow:
$-92.84M
1W Performance:
-13.08%
1M Performance:
+9.74%
6M Performance:
-24.23%
1Y Performance:
-55.59%
1-Day Range:
$0.6601
$0.696
1-Week Range:
$0.6601
$0.7729
52-Week Range:
$0.4471
$1.6399
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.6706 | 56.71M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Building trade automation scripts for Adicet Bio Inc.Low Exposure Strategy with Sector Analysis - Newser
How high can Adicet Bio Inc. stock price go in 2025Free Daily Momentum Screener With Alerts - Newser
Tools to monitor Adicet Bio Inc. recovery probabilityPattern Recognition Tool for ROI Investors - Newser
Sentiment analysis tools applied to Adicet Bio Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Pattern recognition hints at Adicet Bio Inc. upsideBreakout Screener With Alert Based Timing - Newser
Custom watchlist performance reports with Adicet Bio Inc.Predictable Return Plan with Entry Guidance - Newser
Advanced analytics toolkit walkthrough for Adicet Bio Inc.Market Sentiment Tracker with Smart Alerts - Newser
How Adicet Bio Inc. stock performs during market volatilityInvestment Roadmap for High Potential Stocks - Newser
Adicet Bio Inc. stock trend outlook and recovery pathTrading Volume Spike and Reversal Analysis - Newser
Why Adicet Bio Inc. stock attracts strong analyst attentionExit Ready Momentum Stock Watchlist Expanded - beatles.ru
Is Adicet Bio Inc. stock overvalued or undervaluedBest Dividend Outlook For Consistent Profits - jammulinksnews.com
When is Adicet Bio Inc. stock expected to show significant growthLow Risk Target Finder For Every Investor - jammulinksnews.com
What is Adicet Bio Inc. company’s growth strategyFree Investment Risk Control - jammulinksnews.com
What catalysts could drive Adicet Bio Inc. stock higher in 2025Capitalize on fast-moving stock opportunities - jammulinksnews.com
How high can Adicet Bio Inc. stock price go in 2025 Short-Term Swing Opportunity Summary Sheet - Newser
Pattern recognition hints at Adicet Bio Inc. upside AI Intraday Market Movement Prediction Tool - Newser
How does Adicet Bio Inc. compare to its industry peersAchieve breakthrough profits with expert advice - jammulinksnews.com
How does Adicet Bio Inc. generate profit in a changing economyConsistently exceptional gains - jammulinksnews.com
What is the risk reward ratio of investing in Adicet Bio Inc. stockGet timely alerts on top market movers - jammulinksnews.com
Is it the right time to buy Adicet Bio Inc. stockMaximize gains with professional stock picks - jammulinksnews.com
Published on: 2025-07-28 03:52:12 - jammulinksnews.com
How strong is Adicet Bio Inc. company’s balance sheetInvest smarter with daily market updates - jammulinksnews.com
Why is Adicet Bio Inc. stock attracting strong analyst attentionOutstanding risk-reward balance - jammulinksnews.com
What are Adicet Bio Inc. company’s key revenue driversGet daily updates on market movers and shakers - jammulinksnews.com
What makes Adicet Bio Inc. stock price move sharplyFree Deep Market Trend Analysis - Newser
Adicet Bio (NASDAQ:ACET) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
Adicet Bio (NASDAQ:ACET) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates “Buy” Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Q2 Earnings Estimate for Adicet Bio Issued By HC Wainwright - Defense World
Layoff Tracker: Adicet’s Pipeline Optimization Push Claims 30% of Workforce - BioSpace
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
Does Adicet Bio Inc. stock pay reliable dividendsOutperformance with explosive growth - jammulinksnews.com
Is Adicet Bio Inc. a good long term investmentUnstoppable profit momentum - PrintWeekIndia
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 - Yahoo Finance
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - BioSpace
What drives Adicet Bio Inc. stock priceConsistently profitable trades - Autocar Professional
One biotech looks to wind down, another fights to extend its lifeSan Francisco Business Times - The Business Journals
Adicet Bio doses first systemic sclerosis patient in ADI-001 trial - Investing.com Canada
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):